-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on InflaRx, Lowers Price Target to $3

Benzinga·05/29/2025 16:35:56
Listen to the news
Oppenheimer analyst Andreas Argyrides maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 to $3.